Sensorineural hearing loss (SNHL) is the most prevalent form of permanent hearing loss, affecting over 6% of the global ...

The server encountered an error and could not complete your request. If the problem persists, please contact us using the ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi ...

Researchers at the universities of Amsterdam and Utrecht have observed the formation of nanocavities in montmorillonite clay ...

Sierra Leone’s President Julius Maada Bio was on Sunday elected Chairman of the Economic Community of West African States ...

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

Researchers at the universities of Amsterdam and Utrecht have observed the formation of nanocavities in montmorillonite clay under exposure to ...

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.

Formation Bio CEO Benjamine Liu joins 'Fast Money' as Formation comes in at #37 on the Disruptor 50 list. More for You. Early US intelligence report suggests US strikes only set back Iran’s ...

Formation Bio acquires and in-licenses promising drug assets, advancing them through critical development milestones (Phase II and beyond), and then out-licensing for further advancement. The ...